Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
200 participants
INTERVENTIONAL
2024-11-25
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
NCT02921659
Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans
NCT04851288
Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity
NCT06425042
Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging
NCT03818802
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes
NCT02721537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
830 mg Nicotinamide and Placebo
830 mg Nicotinamide supplement capsule and 1 identical Placebo capsule twice a day for 12 weeks
Nicotinamide Riboside Malate
Active supplement.
Placebo
Placebo
1660 mg Nicotinamide
1660 mg Nicotinamide supplement; 2 of the 830 mg capsules twice a day for 12 weeks
Nicotinamide Riboside Malate
Active supplement.
Placebo
2 identical Placebo capsules twice a day for 12 weeks
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide Riboside Malate
Active supplement.
Placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provides consent to participate in the study
* Not pregnant at time of consent
* Understands and agrees to follow all study procedures and limitations
* Have no contraindicating comorbid health condition as determined by the clinical investigators
Exclusion Criteria
* BMI Restrictions: \<30
* Allergy or sensitivity to study agent ingredients
* Hypertension treated with medication
* Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study.
* Surgery planned during the course of the trial
* History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke
* History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis.
* Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index \>40 kg m-2), or weight stable for at least 3 months prior to enrolling in the study (defined as \>2 kg change in body mass).
* An unstable medical or mental health condition as determined by the physician investigator.
40 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ryan T. Hurt, M.D., Ph.D.
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ryan Hurt, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Brent Bauer, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-005288
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.